SMARCA2 and ovarian carcinoma: In this regard, EZH2i have been reported to cause antiproliferative effects in several cancer cell lines including lymphoma cell lines with EZH2-activating mutations [63,64,65] and cancer cell lines with inactivating mutations in subunits of the chromatin-remodeling complex SWI/SNF such as ARID1A-deficient ovarian cancer [66], SMARCA4- and SMARCA2-deficient ovarian cancer [67], and SMARCB1/INI1-deficient rhabdoid tumor and synovial sarcomas cell lines [68,69].